















PATIENT-CENTRED CONSIDERATIONS (DISCUSS AS APPROPRIATE)

	Oral anticoagulant type (warfarin or NOAC or none)	<input type="checkbox"/>		Support with use of oral anticoagulant	<input type="checkbox"/>
	Regimen (once- or twice-daily or no preference)	<input type="checkbox"/>		Involvement of next-of-kin in discussion	<input type="checkbox"/>
	Monitoring preference (yes/no)	<input type="checkbox"/>		Cognitive function	<input type="checkbox"/>
	Antidote availability preference	<input type="checkbox"/>		Medication adherence	<input type="checkbox"/>
	Medication cost	<input type="checkbox"/>		Taken with or without food	<input type="checkbox"/>
	Dosette box	<input type="checkbox"/>		Sources of further information	<input type="checkbox"/>
	Side effects	<input type="checkbox"/>		Co-medication	<input type="checkbox"/>

Source: Adapted from the 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.